Intact Vascular launches clinical trial of Tack system

Intact Vascular said today it launched the Tack Optimized Balloon Angioplasty III clinical trial investigating its Tack endovascular system along with Medtronic‘s (NYSE:MDT) Admiral drug-coated angioplasty balloon for treating peripheral arterial disease. The Tack endovascular system is designed to repair dissections that occur as a complication of balloon angioplasty. The system allows operating physicians to repair dissections with only a small amount of foreign material in the artery, Wayne, Penn.-based Intact Vascular said. “The Tack endovascular system is the ideal adjunct to drug-coated balloon angioplasty. It allows physicians to treat arterial damage in a highly targeted way and address their goals of reducing stress and irritation on the artery. We have a robust clinical development portfolio that is designed to demonstrate the power of this technology combination on the endovascular treatment of PAD,” clinical affairs veep Marc Penna said in a press release. Enrollment for the trial has opened, and the 1st patient in the trial has been treated by Dr. Klaus Brechtel at Berlin, Germany’s Franziskus-Hospital, the company said. “One of our key goals when using drug coated balloons to perform peripheral angioplasty is to minimize inflammation of the treated artery and leave little foreign material behind. The Tack system is designed to allow us to repair arterial damage after angioplasty while minimizing vessel irritation and leaving far le...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Catheters Clinical Trials Vascular Intact Vascular Source Type: news